Search by Drug Name or NDC
NDC 60219-1721-07 etravirine 100 mg/1 Details
etravirine 100 mg/1
etravirine is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Amneal Pharmaceuticals NY LLC. The primary component is ETRAVIRINE.
MedlinePlus Drug Summary
Etravirine is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults and children 2 years of age and older who no longer benefit from taking other HIV medications. Etravirine is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by decreasing the amount of HIV in the blood. Although etravirine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Related Packages: 60219-1721-07Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Etravirine
Product Information
| NDC | 60219-1721 |
|---|---|
| Product ID | 60219-1721_328e5245-4fe7-432d-a025-7cead4bf85d2 |
| Associated GPIs | 12109035000320 |
| GCN Sequence Number | 063597 |
| GCN Sequence Number Description | etravirine TABLET 100 MG ORAL |
| HIC3 | W5K |
| HIC3 Description | ANTIVIRALS, HIV-SPECIFIC, NON-NUCLEOSIDE, RTI |
| GCN | 99318 |
| HICL Sequence Number | 035342 |
| HICL Sequence Number Description | ETRAVIRINE |
| Brand/Generic | Generic |
| Proprietary Name | etravirine |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | etravirine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 100 |
| Active Ingredient Units | mg/1 |
| Substance Name | ETRAVIRINE |
| Labeler Name | Amneal Pharmaceuticals NY LLC |
| Pharmaceutical Class | Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA214196 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 60219-1721-07 (60219172107)
| NDC Package Code | 60219-1721-7 |
|---|---|
| Billing NDC | 60219172107 |
| Package | 120 TABLET in 1 BOTTLE, PLASTIC (60219-1721-7) |
| Marketing Start Date | 2021-06-14 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |